FDA
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and Hub Group, Inc. (NASDAQ: HUBG); Grabar Law Of
-
-
-
-
-
-
-
Aardvark Therapeutics Inc (AARD) PT Lowered to $19 at Jones Trading
-
-
-
-
-
-
-
Morgan Stanley Downgrades Aardvark Therapeutics Inc (AARD) to Equalweight
-
-
-
-
-
-
-
Aardvark doses first patient in Australia for Prader-Willi syndrome trial
-
-
-
-
-
-
-
Aardvark Therapeutics (AARD) announces new management appointments
-
-
-
334,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


